Search Results 1731-1740 of 3953 for Solid

  1. Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radiation Injury After Treatment for Brain Metastases - Mayo Clinic

    It is hypothesized that the addition of bevacizumab to standard care corticosteroids will reduce treatment-induced toxicities and improve neurologic impairments ...

  2. Pulmonary Medicine Clinical Trials - Medical Professionals

    ... Solid Tumors version 1.1 (RECIST 1.1) after initial treatment. Safety and Durability of Sirolimus for Treatment of LAM. Rochester, Minn., Jacksonville, Fla ...

  3. Statins for the Treatment of NASH - Mayo Clinic

    e) Prior solid organ transplant;. f) Any other concurrent condition which, in the opinion of the investigator, could impact adversely on the subject ...

  4. A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma - Mayo Clinic

    Patients with history of solid organ transplantation or hematopoietic stem cell transplantation. 14. Pregnant and breastfeeding patients. 15. Patients with ...

  5. Spirometry - Mayo Clinic

    Healthcare professionals use spirometry to diagnose asthma, chronic obstructive pulmonary disease (COPD) and other conditions that affect the ability to breathe ...

  6. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Effectiveness of Nimacimab in Patients With Diabetic Gastroparesis - Mayo Clinic

    Screening or documented historical scintigraphy (within 3 years prior to screening) with approximately 10% or greater of solid contents retained at 4 hours.

  7. A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib - Mayo Clinic

    The purpose of this study is to compare the objective response rate (ORR) by IRR of ripretinib vs sunitinib using modified Response Evaluation Criteria in Solid ...

  8. Hematology - Clinical trials

    ... Solid Tumors version 1.1 (RECIST 1.1) after initial treatment. Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification ...

  9. Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery - Mayo Clinic

    At least one non-nodal lesion considered measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (that is, a lesion whose longest ...

  10. Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) - Mayo Clinic

    History of a hematologic malignancy, malignant primary brain tumor, malignant sarcoma, or another malignant primary solid tumor, unless no evidence of that ...